Figure 3From: Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary careOmalizumab response: within-patient paired DLQI scores at baseline and lowest recorded on treatment.Back to article page